	US 11,787,767 B2
	Modulators of mas-related g-protein receptor X4 and related products and methods
Marcos Sainz, San Diego, CA (US); Adam Yeager, San Diego, CA (US); Brandon Selfridge, San Diego, CA (US); Esther Martinborough, San Diego, CA (US); Marcus Boehm, San Diego, CA (US); and Liming Huang, San Diego, CA (US)
Assigned to ESCIENT PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Apr. 15, 2021, as Appl. No. 17/231,834.
Claims priority of provisional application 63/011,964, filed on Apr. 17, 2020.
Prior Publication US 2021/0340106 A1, Nov. 4, 2021
Int. Cl. C07D 215/227 (2006.01); C07D 209/34 (2006.01); C07D 209/46 (2006.01); C07D 217/24 (2006.01); C07D 413/12 (2006.01)

CPC C07D 215/227 (2013.01) [C07D 209/34 (2013.01); C07D 209/46 (2013.01); C07D 217/24 (2013.01); C07D 413/12 (2013.01)]

8 Claims

1. A compound having the structure of Formula (IX):

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein:

R^2ais alkyl;

R^2cis H, halo, alkyl, haloalkyl, or aralkyl;

each R³is, independently, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, carbocycle or heterocycle, —CN, —(CH₂)_qC(O)OR⁴, —(CH₂)_qNHR⁵, —(CH₂)_qOR⁶, —C(O)NR⁷R⁸, or a carboxylic acid isostere;

each R⁴, R⁵, R⁶, and R⁷is, independently, H or alkyl;

each R⁸is, independently, H, —SO₂CH₃, carbocycle, heterocycle, or alkyl,

wherein each R⁸is independently substituted with 0, 1, 2, or 3 R⁹;

each R⁹is —OH, —CN, —NR′R″, —C(O)OH, —C(O)NR′R″, —SO₂OH, alkoxy, carbocycle, or heterocycle;

each R′ is, independently, H or alkyl;

each R″ is, independently, H or alkyl;

p is 0-3; and

q is 0-6.